{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+II&page=70",
    "query": {
      "intervention": "Control II",
      "page": 70
    },
    "page_size": 10
  },
  "pagination": {
    "page": 70,
    "page_size": 10,
    "total_count": 2669,
    "total_pages": 267,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+II&page=71&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+II&page=69&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-01T10:30:32.840Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00230191",
      "title": "Safety and Efficacy of RK0202 in Oral Mucositis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mouth Diseases",
        "Mouth Ulcers",
        "Oral Mucositis",
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "RK-0202",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RxKinetix",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2003-01",
      "completion_date": "2005-12",
      "has_results": false,
      "last_update_posted_date": "2007-01-15",
      "last_synced_at": "2026-11-01T10:30:32.840Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Tampa, Florida • Louisville, Kentucky + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Farmington",
          "state": "Massachusetts"
        },
        {
          "city": "Toledo",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00230191"
    },
    {
      "nct_id": "NCT00630370",
      "title": "A Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post Prandial Distress Syndrome"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "20 mg ATI 7505",
          "type": "DRUG"
        },
        {
          "name": "40 mg ATI 7505",
          "type": "DRUG"
        },
        {
          "name": "80 mg ATI 7505",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Procter and Gamble",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 6,
      "start_date": "2008-02",
      "completion_date": "2008-07",
      "has_results": false,
      "last_update_posted_date": "2009-06-17",
      "last_synced_at": "2026-11-01T10:30:32.840Z",
      "location_count": 44,
      "location_summary": "Chino, California • Fresno, California • Los Angeles, California + 37 more",
      "locations": [
        {
          "city": "Chino",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00630370"
    },
    {
      "nct_id": "NCT00379938",
      "title": "B-19 Parvovirus Vaccine Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Parvovirus B19 Infection"
      ],
      "interventions": [
        {
          "name": "VAI-VP705 (parvovirus B-19 vaccine)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "MF-59",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 43,
      "start_date": "2006-08",
      "completion_date": "2008-10",
      "has_results": false,
      "last_update_posted_date": "2011-08-15",
      "last_synced_at": "2026-11-01T10:30:32.840Z",
      "location_count": 3,
      "location_summary": "Baltimore, Maryland • Cincinnati, Ohio • Houston, Texas",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00379938"
    },
    {
      "nct_id": "NCT04976855",
      "title": "Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer",
        "Opioid-use Disorder"
      ],
      "interventions": [
        {
          "name": "INDV-2000",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "SUBOXONE® sublingual film",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indivior Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 64,
      "start_date": "2022-08-17",
      "completion_date": "2023-07-05",
      "has_results": true,
      "last_update_posted_date": "2024-08-21",
      "last_synced_at": "2026-11-01T10:30:32.840Z",
      "location_count": 3,
      "location_summary": "Baltimore, Maryland • DeSoto, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "DeSoto",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04976855"
    },
    {
      "nct_id": "NCT02150343",
      "title": "Phase II HDM-SPIRE Safety and Efficacy Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rhinoconjunctivitis"
      ],
      "interventions": [
        {
          "name": "HDM-SPIRE",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Circassia Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 715,
      "start_date": "2014-09",
      "completion_date": "2017-04-13",
      "has_results": true,
      "last_update_posted_date": "2018-06-15",
      "last_synced_at": "2026-11-01T10:30:32.840Z",
      "location_count": 56,
      "location_summary": "Birmingham, Alabama • Huntington Beach, California • Long Beach, California + 53 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Napa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02150343"
    },
    {
      "nct_id": "NCT01038752",
      "title": "Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Suramin Drug:Docetaxel Drug: Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo Drug: Docetaxel Drug: Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Optimum Therapeutics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2010-08",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2015-05-21",
      "last_synced_at": "2026-11-01T10:30:32.840Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Richmond, Virginia",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01038752"
    },
    {
      "nct_id": "NCT00020735",
      "title": "Toremifene Followed by Radical Prostatectomy in Treating Patients With Stage I or Stage II Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "toremifene",
          "type": "DRUG"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "neoadjuvant therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Joel Nelson, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "MALE",
        "summary": "18 Years to 120 Years · Male only"
      },
      "enrollment_count": 45,
      "start_date": "2001-04",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2015-12-02",
      "last_synced_at": "2026-11-01T10:30:32.840Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00020735"
    },
    {
      "nct_id": "NCT01872689",
      "title": "A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "Lebrikizumab",
          "type": "DRUG"
        },
        {
          "name": "Pirfenidone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 505,
      "start_date": "2013-10-13",
      "completion_date": "2017-11-06",
      "has_results": true,
      "last_update_posted_date": "2018-08-24",
      "last_synced_at": "2026-11-01T10:30:32.840Z",
      "location_count": 54,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 47 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01872689"
    },
    {
      "nct_id": "NCT02931552",
      "title": "Nuevo Amanecer II: Translating a Stress Management Program for Latinas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Psychology, Social"
      ],
      "interventions": [
        {
          "name": "Nuevo Amancer-II Stress Management Program",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 153,
      "start_date": "2016-09",
      "completion_date": "2019-02",
      "has_results": false,
      "last_update_posted_date": "2019-04-05",
      "last_synced_at": "2026-11-01T10:30:32.840Z",
      "location_count": 1,
      "location_summary": "Multiple Locations, California",
      "locations": [
        {
          "city": "Multiple Locations",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02931552"
    },
    {
      "nct_id": "NCT04292535",
      "title": "Safety and Efficacy of Combining Intranasal Insulin & Acute Exercise",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Insulin",
        "Exercise"
      ],
      "interventions": [
        {
          "name": "Placebo into the intranasal mucosa",
          "type": "DRUG"
        },
        {
          "name": "20 IU NovoLog Insulin aspart into the intranasal mucosa",
          "type": "DRUG"
        },
        {
          "name": "40 IU NovoLog Insulin aspart into the intranasal mucosa",
          "type": "DRUG"
        },
        {
          "name": "60 IU NovoLog Insulin aspart into the intranasal mucosa",
          "type": "DRUG"
        },
        {
          "name": "80 IU NovoLog Insulin aspart into the intranasal mucosa",
          "type": "DRUG"
        },
        {
          "name": "100 IU NovoLog Insulin aspart into the intranasal mucosa",
          "type": "DRUG"
        },
        {
          "name": "120 IU NovoLog Insulin aspart into the intranasal mucosa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Michigan State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 116,
      "start_date": "2018-06-15",
      "completion_date": "2020-02-20",
      "has_results": true,
      "last_update_posted_date": "2021-06-21",
      "last_synced_at": "2026-11-01T10:30:32.840Z",
      "location_count": 1,
      "location_summary": "East Lansing, Michigan",
      "locations": [
        {
          "city": "East Lansing",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04292535"
    }
  ]
}